PainChek Ltd (AU:PCK)
ASX:PCK
Want to see AU:PCK full AI Analyst Report?
PCK Stock Chart & Stats
AU$0.29
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.29
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.13 - AU$1.05
Previous CloseN/A
Volume838.67K
Average Volume (3M)3.56M
Market Cap
AU$28.22M
Enterprise ValueAU$23.43M
Total Cash (Recent Filing)AU$4.78M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta0.98
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding209,007,310
10 Day Avg. Volume1,466,878
30 Day Avg. Volume3,559,149
Financial Highlights & Ratios
PEG Ratio0.48
Price to Book (P/B)-70.25
Price to Sales (P/S)23.25
P/FCF Ratio-11.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetHaving no debt materially reduces solvency and refinancing risk and preserves financial flexibility. Over months this allows management to prioritise commercial rollouts, partner investments or product development without interest burdens, improving strategic optionality while cash burn is addressed.
Recurring SaaS Revenue ModelA subscription/usage-based SaaS model yields recurring, contractable revenue that scales with sites/residents. This creates predictable cash flows and customer stickiness via onboarding/training, supporting durable revenue expansion in aged-care verticals as the company upsells and expands deployments.
Improving Revenue And Unit EconomicsAccelerating top-line growth alongside rising gross margin indicates improving product-market fit and better unit economics. If sustained, this trend can enable operating leverage: growing revenue should absorb fixed costs and help narrow losses over a 2-6 month horizon absent material cost shocks.
Bears Say
Heavy Cash BurnPersistently negative operating and free cash flow rapidly depletes liquid resources and forces reliance on external financing. Over the medium term this raises dilution risk, constrains discretionary spending on commercial expansion, and heightens execution pressure if funding gaps emerge.
Deep UnprofitabilityA very large negative net margin shows operating costs far exceed revenue, meaning current scale does not support profitability. Structurally, closing such a gap requires sustained revenue acceleration or meaningful cost restructuring, both of which carry execution risk over several months.
Negative Shareholders' EquityEroded equity reduces the capital buffer against shocks and can impair access to debt or favourable financing. Over a 2-6 month horizon, negative equity increases dependence on new capital raises or restructuring, raising strategic vulnerability and potential dilution for existing shareholders.
PainChek Ltd News
PCK FAQ
What was PainChek Ltd’s price range in the past 12 months?
PainChek Ltd lowest share price was AU$0.13 and its highest was AU$1.05 in the past 12 months.
What is PainChek Ltd’s market cap?
PainChek Ltd’s market cap is AU$28.22M.
When is PainChek Ltd’s upcoming earnings report date?
PainChek Ltd’s upcoming earnings report date is Aug 28, 2026 which is in 101 days.
How were PainChek Ltd’s earnings last quarter?
PainChek Ltd released its earnings results on Feb 27, 2026. The company reported -AU$0.023 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.023.
Is PainChek Ltd overvalued?
According to Wall Street analysts PainChek Ltd’s price is currently Overvalued.
Does PainChek Ltd pay dividends?
PainChek Ltd does not currently pay dividends.
What is PainChek Ltd’s EPS estimate?
PainChek Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PainChek Ltd have?
PainChek Ltd has 209,007,310 shares outstanding.
What happened to PainChek Ltd’s price movement after its last earnings report?
PainChek Ltd reported an EPS of -AU$0.023 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.556%.
Which hedge fund is a major shareholder of PainChek Ltd?
Currently, no hedge funds are holding shares in AU:PCK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
PainChek Ltd Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:PCK Sentiment 100%
Sector Average 72%
Sector Average 72%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.03%
12-Months-Change
Fundamentals
Return on Equity
-1009.84%
Trailing 12-Months
Asset Growth
7.04%
Trailing 12-Months
Company Description
PainChek Ltd
PainChek Limited develops and commercializes mobile medical device applications that provides pain assessment for individuals. The company offers PainChek, which uses camera in smartphones and tablets to capture video that is analyzed in real time using facial recognition software to indicate the presence of the pain. It serves patients suffering with dementia. The company was formerly known as ePAT Technologies Ltd and changed its name to PainChek Limited in January 2018. PainChek Limited is based in Sydney, Australia.
Technical Analysis
Mach7 Technologies
―
Resonance Health Ltd
―
Beamtree Holdings Ltd
―
―
Alcidion Group Limited
―
Options Prices
Currently, No data available
---